For Quick Alerts
For Daily Alerts

Sun Pharma Q1 2014 revenues rises 31 per cent on strong US performance


Sun Pharma Q1 2014 revenues rises 31 per cent
Sun Pharmaceutical Industries: Quotes, News
BSE 438.20BSE Quote10.3 (-2.35%)
NSE 439.40NSE Quote9.2 (-2.09%)
Sun Pharma has reported a solid set of results with revenues at Rs. 3482 crores, a growth of 31% over same quarter last year.

Adjusted for the impact of one-time sales recorded in the domestic business in Q4FY12, which lowered Q1FY13 sales,

the net sales have grown by 23% over Q1FY13.

The branded generic sales in India, at Rs. 849 crores, grew by 44% over Q1 last year. Adjusted sales growth of

the domestic formulation business, as explained above, is 11%.

On the other hand the US finished dosages sale was at US$ 364 million recording a growth of 28% (in US$ terms) over Q1 last year.

"International formulation sales is US$ 81 million, and grew by 19% (in US$ terms) over same quarter last

year. EBITDA at Rs. 1531 crores grew by 26% YoY while EBITDA margins were at 44%, compared to 46% in Q1

last year," the company has said in a release.

The company has reported net loss at Rs. 1276 crores, on account of a provision of Rs 2517 crores towards settlement for patent infringement litigation related to generic versions of ‘Protonix'.

Dilip Shanghvi, Managing Director of the Company said, "All our businesses continue to perform in-line with our

expectations. We remain focused on strengthening our existing businesses and developing a differentiated and

specialty driven product basket. We also continue to review opportunities to expand and strengthen our global


Read more about: sun pharma q12014
Story first published: Saturday, August 10, 2013, 10:06 [IST]
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more